20 Mid Cap Stocks Hit 52-Week Highs On Thursday
A fresh list of market leaders includes notable clusters in health care, but the real story is in the valuations.
Revolution Medicines (RVMD), with a market value of about $39.2 billion, is the largest of 20 Mid Cap stocks hitting a 52-week high on Thursday. The list shows clusters in Biotechnology and Life & Health Insurance, with 3 names from each industry.
With several names posting strong one-month gains, the central question is what kind of price leadership this is. Below is the full list of names reaching new highs.
The Biggest Names On The List
The table below shows the 10 largest of the 20 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| RVMD | $39.2 Bil | 0.3% | 2.9% | 4.2% | 415.3% |
| NTAP | $38.1 Bil | 2.6% | 10.1% | 16.1% | 91.0% |
| TPR | $32.8 Bil | 1.8% | 6.2% | 15.6% | 47.2% |
| ATI | $30.5 Bil | 8.9% | 22.8% | 20.4% | 200.0% |
| CPAY | $26.9 Bil | 1.0% | 2.1% | 15.2% | 25.0% |
| DGX | $26.5 Bil | 1.1% | 1.8% | 14.5% | 40.1% |
| LH | $26.1 Bil | 0.8% | 0.3% | 14.0% | 21.4% |
| PFG | $25.1 Bil | 0.5% | 1.3% | 4.2% | 57.2% |
| USFD | $23.5 Bil | 6.4% | 6.4% | 7.1% | 29.8% |
| ROKU | $22.1 Bil | 2.1% | 3.4% | 7.8% | 79.4% |
Has the price run ahead of the business?
ATI (ATI) shows the strongest one-month run on the list, up 20.4%. That performance has brought its valuation to 71.8 times trailing earnings, while its revenue grew 2.9% over the last twelve months.
Compare that to Corpay (CPAY). The company trades at 22.9 times trailing earnings, but its revenue grew 18.3% over the same period, with an operating margin of 42.6%. The contrast highlights the different paths stocks can take to a new high.
A new high is a question, not a verdict.
A 52-week high signals that a stock has strong positive price action. This strength can often persist. But a price is not a business, and a new high is not a fundamental judgment on value.
The disciplined next step is always the same: to look past the chart and determine if the company’s operating results justify the new, higher valuation. The price is the beginning of the work, not the end.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
New Highs Fade. Discipline Compounds
Some of the names on this list will keep setting highs for years, and some are at the top of their run right now. Sorting one from the other, name by name, every day, is the work most investors never keep up with.
That sorting is what the Trefis High Quality (HQ) Portfolio does systematically: about 30 quality businesses screened for the fundamentals that sustain a run, held with rules instead of excitement. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Use the high list for ideas; use the portfolio for the compounding.